Loading
Formycon AG Stock: price and insider trades · Germany
Formycon AG: what insiders have been doing
Formycon AG, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to BaFin. In the past year (18 October 2025 to 18 October 2026), 3 filings came from 2 insiders.
The flow runs one way only: 3 sales worth €858k, from 2 insiders, and no purchase. Biggest ticket of the year: €665k, sold by Active Ownership Fund SICAV SIF SCS and made public on 14 January 2026.
Compared with its exchange (287 companies, median 5 filings), a count of 3 filings is below the norm. Over the whole record (from 2026), the tally stands at no purchases and 3 sales.
Typically, a trade is published a median of 7 days after it takes place. For comparison, MAR article 19 gives managers three business days to notify a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. Every figure here comes from the filings published by BaFin and describes the past, not future prices; it is not investment advice.
Insider Decl.
3
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€857,750
3 ops. · all time
Who traded when
BuySaleActive Ownership Fund SICAV SIF SCS4 sales
Fundamental score
Ranked 23,322 of 24,148 companies
13.2
score / 100
Value12
Quality14
FCF yld-13%
Earn yld-19%
EV/EBITDA·
ROE-6.3%
Gross mgn8.0%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€19.06
Analyst consensus
6 analysts1.43/5
€30.00Target €39.67(+108%)€51.00
Income statement
Revenue€44.5M
Gross profit€3.6M8% margin
EBITDA-€888k-2% margin
Net income-€64.7M-41.0% margin
Valuation
PER (forward)17.1x
P/Book0.9x
Beta0.70
Balance sheet & cash
Market cap€336.8M
Total debt€9.6M
Free Cash Flow-€44.1M
Debt / Equity2%
Profitability & ownership
ROE-6.3%
ROA-1.3%
% insiders30.4%
% institutions31.3%
Last declaration on 15 January 2026
Declarations3 total
1,000 shares@ €96.5011.3% of flowDebt instrumentISIN NO0013586024BAFIN:40013574-e1f6e70a09b4
1,000 shares@ €96.2511.2% of flowDebt instrumentISIN NO0013586024BAFIN:40013574-6199863bb185
7,000 shares@ €95.0077.5% of flowDebt instrumentBAFIN:40013574
3 of 3 declarations
About Formycon AG
Formycon AG is a German biosimilars specialist listed on Xetra/Frankfurt (DAX/MDAX/SDAX), headquartered in Planegg-Martinsried near Munich, Germany. The company positions itself as an independent developer of high-quality biosimilars, i.e. follow-on biologic medicines designed to provide patients and healthcare systems with more affordable alternatives to already marketed reference biologics. Its business model is based on identifying biologic molecules with strong commercial potential, executing preclinical and clinical development, obtaining regulatory approvals, and monetizing assets through licensing and commercialization partnerships with international pharma companies. ([formycon.com](https://www.formycon.com/en/company/about-us/?utm_source=openai))
Formycon was built at the intersection of the biosimilars industry’s emergence and the need for specialized development expertise. Over time, it has assembled a team with deep scientific, clinical, manufacturing-process, and regulatory know-how, including professionals who helped bring some of the world’s first biosimilars to market. The company’s platform is focused on comparability analytics, process development, and clinical execution. Its pipeline includes FYB201 (ranibizumab, a biosimilar candidate to Lucentis®), FYB203 (aflibercept, a biosimilar candidate to Eylea®), FYB202 (ustekinumab, a biosimilar candidate to Stelara®), and FYB206 (pembrolizumab, a biosimilar candidate to Keytruda®). Additional earlier-stage programs extend the optionality of the portfolio. ([formycon.com](https://www.formycon.com/en/pipeline/?utm_source=openai))
Read moreShow less
In competitive terms, Formycon operates in a demanding global market populated by large pharma companies, biosimilar/generic specialists, and powerful commercialization partners. Its differentiation lies in its regulatory and clinical execution capabilities, its ability to secure global partnerships, and its exposure to several large therapeutic franchises, particularly ophthalmology, immunology, and oncology. At the same time, the company is exposed to the usual biosimilar-sector risks: pricing pressure, intense competition, regulatory timing, manufacturing complexity, and reliance on partners for market access and launch execution. ([formycon.com](https://www.formycon.com/en/company/about-us/?utm_source=openai))
Recent highlights show continued portfolio maturation and commercialization progress. In 2025, FYB202/Otulfi® received interchangeable biosimilar status in the United States, while FYB203/AHZANTIVE® advanced through approvals and commercialization agreements, including in Europe and North America. In February 2025, Formycon decided to discontinue the Phase III Lotus trial for FYB206 after positive FDA feedback on the comparability strategy, favoring an analytical package supported by an ongoing Phase I PK study. More recently, the company published preliminary 2025 figures and indicated revenue momentum supported by upfront payments linked to FYB206 and disciplined cost control. ([formycon.com](https://www.formycon.com/blog/press-release/formycon-und-fresenius-kabi-geben-fda-zulassung-von-fyb202-otulfi-ustekinumab-aauz-als-austauschbares-biosimilar-interchangeable-bekannt/?utm_source=openai))
For investors, Formycon is best viewed as a specialty growth story at the intersection of science, regulation, and partnering, with valuation and execution closely tied to pipeline success and commercialization progress across the U.S., Europe, and other international markets.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
